The heat shock protein 90 inhibitor RGRN-305 attenuates SARS-CoV-2 spike protein-induced inflammation in vitro but lacks effectiveness as COVID-19 treatment in mice
PLOS ONE · 26.09.2024 · 19 (9) · e0310915
DOI: 10.1371/journal.pone.0310915 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 26.09.2024. Verfasst von Hakim Ben Abdallah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Aarhus University Hospital, Aarhus N, Denmark. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, SARS-CoV-2, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kongelig Hofbuntmager Aage Bangs Fond.
Abstract (Originalsprache)
The inhibition of heat shock protein 90 (HSP90), a molecular chaperone, has been proposed to be a potential novel treatment strategy for Coronavirus disease 2019 (COVID-19). In contrast to other studies, our data demonstrated that RGRN-305, a HSP90 inhibitor, exacerbated the cytopathic effect and did not reduce the viral shedding in VeroE6-hTMPRSS2 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Likewise in a murine model of SARS-CoV-2, transgenic mice treated orally with RGRN-305 exhibited reduced survival by the end of the experiment (day 12) as 14% (1/7) survived compared to 63% (5/8) of those treated with drug-vehicle. Animal weight was not reduced by the RGRN-305 treatment. Interestingly, we demonstrated that inhibition of HSP90 by RGRN-305 significantly dampened the inflammatory response induced by SARS-CoV-2 spike protein in human macrophage-like cells (U937) and human lung epithelial cells (A549). Measured by quantitative real-time PCR, the mRNA expression of the proinflammatory cytokines TNF , IL1B and IL6 were significantly reduced. Together, these data suggest that HSP90 inhibition by RGRN-305 exacerbates the SARS-CoV-2 infection in vitro and reduces the survival of mice infected with SARS-CoV-2, but exhibits strong anti-inflammatory properties. This data shows that while RGRN-305 may be helpful in a ‘cytokine storm’, it has no beneficial impact on viral replication or survival in animals as a monotherapy. Further animal studies with HSP90 inhibitors in combination with an anti-viral drug may provide additional insights into its utility in viral infections and whether HSP90 inhibition may continue to be a potential treatment strategy for COVID-19 disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Aarhus University Hospital, Aarhus N, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
ORCID-Profile: Hakim Ben Abdallah
Förderung
- Kongelig Hofbuntmager Aage Bangs Fond
Zitieren
APA
Ben Abdallah, H., Marino, G., Idorn, M., S Reinert, L., Bregnhøj, A., Paludan, S. R., & Johansen, C. (2024). The heat shock protein 90 inhibitor RGRN-305 attenuates SARS-CoV-2 spike protein-induced inflammation in vitro but lacks effectiveness as COVID-19 treatment in mice. PLOS ONE, 19(9), e0310915. https://doi.org/10.1371/journal.pone.0310915
Vancouver
Ben Abdallah H, Marino G, Idorn M, S Reinert L, Bregnhøj A, Paludan SR, et al. The heat shock protein 90 inhibitor RGRN-305 attenuates SARS-CoV-2 spike protein-induced inflammation in vitro but lacks effectiveness as COVID-19 treatment in mice. PLOS ONE. 2024;19(9):e0310915. doi:10.1371/journal.pone.0310915
BibTeX
@article{BenAbdallah2024,
author = {Ben Abdallah, Hakim and Marino, Giorgia and Idorn, Manja and S Reinert, Line and Bregnhøj, Anne and Paludan, Søren Riis and Johansen, Claus},
title = {The heat shock protein 90 inhibitor RGRN-305 attenuates SARS-CoV-2 spike protein-induced inflammation in vitro but lacks effectiveness as COVID-19 treatment in mice},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {9},
pages = {e0310915},
doi = {10.1371/journal.pone.0310915}
}
EUVIMED